Actionable Molecular Biomarkers in Primary Brain Tumors

Verena Staedtke, Omar Dildar a. Dzaye, Matthias Holdhoff

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Recent genome-wide studies of malignancies of the central nervous system (CNS) have revolutionized our understanding of the biology of these tumors. This newly gained knowledge provides a wealth of opportunity for biomarker-driven clinical research. To date, however, only few of the available molecular markers truly influence clinical decision-making and treatment. The most widely validated markers in neuro-oncology presently are: (i) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma; (ii) codeletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas; (iii) IDH1/2 mutations; and (iv) select pathway-associated mutations. This article focuses on currently impactful biomarkers in adult and pediatric brain cancers and it provides a perspective on the direction of research in this field.

Original languageEnglish (US)
Pages (from-to)338-349
Number of pages12
JournalTrends in Cancer
Issue number7
StatePublished - Jul 1 2016


  • BRAF mutation
  • IDH mutation
  • biomarker
  • codeletion MGMT promoter methylation
  • codeletion of 1p/19q
  • glioblastoma
  • glioma
  • medulloblastoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Actionable Molecular Biomarkers in Primary Brain Tumors'. Together they form a unique fingerprint.

Cite this